GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Ajanta Pharma Ltd

Ajanta Pharma Board meeting scheduled May 5, 2026 for Q4 FY26 results

RESULTS ● No Immediate Change LOW RISK
📅 Filed on BSE: 21 Apr 2026, 03:59 PM IST  ·  BSE ID: 9ba2045f-2223-46d4-9c93-73f8948c260d
View Original BSE Filing (PDF)
💡
In Simple Terms
Ajanta Pharma's board is scheduled to meet May 5, 2026 to approve and release its full-year financial results.
🤖 AI Summary
  • Board meeting scheduled 5 May 2026 to approve Q4 and full-year FY26 audited results
  • Covers both consolidated and standalone financial statements for year ended 31 March 2026
  • Filed under Regulation 29 of SEBI Listing Regulations—routine board notification
  • No financial data disclosed in this notice; results will be announced after board approval
👥 What This Means For Shareholders
✅
Action Required
No action required at this stage. Monitor BSE for results announcement after 5 May 2026.
👤
Who Is Affected
All shareholders holding Ajanta Pharma shares on record date (to be specified with results). Results will show earnings per share and inform dividend eligibility.
🔍
Management Signal
Routine board scheduling signals normal governance process; no strategic signals disclosed in this notice.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Results announcement filing after 5 May 2026 board meeting—track for FY26 revenue and profit
Dividend announcement—check if company declares dividend from FY26 earnings and record date
Earnings per share (EPS) for FY26—compare against FY25 to assess profitability trend
LOW RISK Routine board meeting notice. No material operational, financial, or governance risks disclosed.
💡 Investor Takeaway
Ajanta Pharma's full-year FY26 audited results will be approved and disclosed after the board meeting on 5 May 2026. The filing contains no financial data—investors must track the actual results announcement for revenue, profit, and dividend details.
⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.